S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|UPDATE: Regeneron skids on shortfall in Eylea sales|
|Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma|
|Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan|
|Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis|
|Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments|
|Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year|
|EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study|
|Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan|
|Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis|
|Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol|
Click above to view more mutual fund data and stats for regn - Regeneron Pharmaceuticals Inc.